TECHWIRE 30
(CIX: WRAL30)  1,173.56  down arrow-0.11  (-0.01 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NQ: Apple)  126.44    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NY: QUINTILES)  72.80    (0 %)  Updated: 06:40 PM EDT, Jul 02 2015
(OP: BASF SE)  88.42    (0 %)  Updated: 05:20 PM EDT, Jul 02 2015
(NQ: BioCryst)  15.10    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NQ: BioDelivery)  7.79    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NQ: CEMP)  33.39    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NQ: Cisco Systems)  27.33    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NQ: Cree)  25.52    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NQ: DARA)  0.89    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NY: EMC CORPORATION)  26.50    (0 %)  Updated: 06:40 PM EDT, Jul 02 2015
(NQ: Extreme Networks)  2.59    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NQ: FB)  87.29    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NY: GLAXOSMITHKLINE)  42.26    (0 %)  Updated: 06:40 PM EDT, Jul 02 2015
(NQ: GOOG)  523.40    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NY: IBM)  165.09    (0 %)  Updated: 06:40 PM EDT, Jul 02 2015
(NY: LH)  120.75    (0 %)  Updated: 06:40 PM EDT, Jul 02 2015
(OP: Lenovo Group)  26.72    (0 %)  Updated: 05:20 PM EDT, Jul 02 2015
(NY: MRK)  57.67    (0 %)  Updated: 06:40 PM EDT, Jul 02 2015
(NQ: Microsoft Corp)  44.40    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NQ: NTAP)  31.50    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NY: NOVARTIS AG)  99.80    (0 %)  Updated: 06:40 PM EDT, Jul 02 2015
(OP: Novozymes A/S)  48.56    (0 %)  Updated: 05:20 PM EDT, Jul 02 2015
(NY: PFIZER)  33.37    (0 %)  Updated: 06:40 PM EDT, Jul 02 2015
(NQ: Pozen)  10.70    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NY: RED HAT)  76.88    (0 %)  Updated: 06:40 PM EDT, Jul 02 2015
(NQ: BBRY)  7.96    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  14.16    (0 %)  Updated: 08:10 PM EDT, Jul 02 2015

Posts tagged “Salix”

August 25, 2005

Premium Lock Drug Manufacturer Salix Suggests Better Treatment for Relief of Cancer Side Effects

Study suggests relief is in site for patients receiving medical treatment for prostate cancer. Drug may have a new purpose.

Tags: Salix
August 9, 2005

Premium Lock Earnings: Salix Reports Surge in Profits; Inspire Revenues Climb

Salix produces 13-cent a share profit as sales far outpace expenses; Inspire cuts losses as co-marketed drug sales increase; Icagen reports a loss but notes progress on drugs.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith